Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NASDAQ: TEM) over potential Wrongdoing

An investigation was announced for current long-term investors in shares of Tempus AI, Inc. (NASDAQ: TEM) concerning potential breaches of fiduciary duties by certain directors and officers of Tempus AI, Inc..

Investors who are current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: TEM stocks follows a lawsuit filed against Tempus AI, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: TEM stocks, concerns whether certain Tempus AI, Inc. officers and directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2024 and May 27, 2025, Tempus AI, Inc. branded itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements, that the Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding, that Tempus AI, Inc. often reported on its relationship with long-term customer AstraZeneca as an example, that importantly between August 6, 2024 and May 27, 2025, Tempus AI, Inc. announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI, that the Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market, that Tempus AI, Inc. additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired between August 6, 2024 and May 27, 2025, and that Tempus AI, Inc. claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.

Those who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.